Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab

  1. Motzer, R.
  2. George, S.
  3. Merchan, J.R.
  4. Hutson, T.E.
  5. Song, X.
  6. Perini, R.F.
  7. Xie, R.
  8. Bapat, U.
  9. Puente, J.
Aldizkaria:
Oncologist

ISSN: 1549-490X,  1083-7159

Argitalpen urtea: 2023

Alea: 28

Zenbakia: 6

Orrialdeak: 501-509

Mota: Artikulua

DOI: 10.1093/ONCOLO/OYAC269 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus